Aurora Cannabis Continues to Slide as It Announces Fresh Cuts

: ACB | Aurora Cannabis Inc. News, Ratings, and Charts

ACB – Aurora Cannabis (ACB) recent layoffs have contributed to its downward price momentum.

Aurora Cannabis (ACB) continues to scale back its European operations as part of its lower cost transformation plan. ACB is aggressively doing everything in its power to minimize SG&A expenses to become a lean, efficient business. 

On Monday, a spokesperson for ACB said about one-quarter of the workforce in select countries, and the company’s European regional office would be eliminated as a result of the decision. ACB’s spokesperson stated in an email that, “Aurora has undertaken a thorough analysis of our international operations to better align to current market conditions, continue to meet market demand and drive the company to near-term profitability. We are committed to simplifying all aspects of our business and applying greater efficiency to our operations.”

These cuts come shortly after ACB announced massive layoffs in their Canadian operations just last month. The company will be closing 5 facilities for a combined 700 job cuts, resulting in a $60 million dollar charge next quarter. The company also cut an additional 500 jobs at the start of the year while announcing over $1 billion in write-downs.

Despite the downsizing, ACB did announce on Monday, they plan to increase production in Denmark. The company will acquire an outstanding 49 percent stake in its Danish business. Mads Ulrik Peterson, the CEO of Aurora Nordic Cannabis, will now be in control of operations in the area as President of the European organization.

This comes after the company announced last week that they were in serious talks with Aphria (APHA) regarding a potential merger, but negotiations fell apart last minute.

The stock continued its downtrend and fell another 2.8% on Monday to close at $11.54. Until investors get more clarity surrounding management, ACB could be headed back to the single digits. Investors may want to consider waiting on the sidelines in the meantime. 

(Disclosure: The author is long ACB)

Want More Great Investing Ideas?

9 “BUY THE DIP” Growth Stocks for 2020

Newly REVISED 2020 Stock Market Outlook

7 “Safe-Haven” Dividend Stocks for Turbulent Times


ACB shares were trading at $11.61 per share on Tuesday afternoon, up $0.07 (+0.61%). Year-to-date, ACB has declined -55.21%, versus a 2.07% rise in the benchmark S&P 500 index during the same period.


About the Author: Aaron Missere


Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ACBGet RatingGet RatingGet Rating
APHAGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Aurora Cannabis Inc. (ACB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ACB News